To assess if co-treatment with honokiol and erlotinib induces higher anti-proliferative and proapoptotic effects than the individual drugs, 1170 cells and EGFR mutant and erlotinib resistant H1650 and H1975 NSCLC cells were treated with honokiol and erlotinib, individually or in combination, for 48 h. This evidence concerns the gene EGFR and non-small cell lung carcinoma.